Sodium-glucose transporter 2 inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Sodium-glucose transporter 2 inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Sodium-glucose transporter 2 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Sodium-glucose transporter 2 inhibitors: Overview
SGLT2 inhibitors, also called gliflozins, are a class of medications that alter essential physiology of the nephron; unlike SGLT1 inhibitors that modulate sodium/glucose channels in the intestinal mucosa. They act by inhibiting sodium-glucose transport protein 2 (SGLT2). SGLT2 inhibitors are used in the treatment of type II diabetes mellitus (T2DM).
Function - SGLT2 is a member of the sodium glucose cotransporter family which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney. SGLT2 is located in the early proximal tubule, and is responsible for reabsorption of 80-90% of the glucose filtered by the kidney glomerulus. Most of the remaining glucose absorption is by sodium/glucose cotransporter 1 (SGLT1) in more distal sections of the proximal tubule.
Sodium-glucose transporter 2 inhibitors - Sodium Glucose cotransporters (SGLTs) are proteins that occur primarily in the kidneys and play an important role in maintaining glucose balance in the blood. SGLT1 and SGLT2 are the two most known SGLTs of this family. SGLT2 is the major transport protein and promotes reabsorption from the glomerular filtration glucose back into circulation and is responsible for approximately 90% of the kidney's glucose reabsorption. SGLT2 is mainly expressed in the kidneys on the epithelial cells lining the first segment of the proximal convoluted tubule. By inhibiting SGLT2, gliflozins prevent the kidneys' reuptake of glucose from the glomerular filtrate and subsequently lower the glucose level in the blood and promote the excretion of glucose in the urine.
Sodium-glucose transporter 2 inhibitors Emerging Drugs Chapters
This segment of the Sodium-glucose transporter 2 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sodium-glucose transporter 2 inhibitors Emerging Drugs
Further product details are provided in the report……..
Sodium-glucose transporter 2 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Sodium-glucose transporter 2 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Sodium-glucose transporter 2 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sodium-glucose transporter 2 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sodium-glucose transporter 2 inhibitors drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Sodium-glucose transporter 2 inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Sodium-glucose transporter 2 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Sodium-glucose transporter 2 inhibitors: Overview
SGLT2 inhibitors, also called gliflozins, are a class of medications that alter essential physiology of the nephron; unlike SGLT1 inhibitors that modulate sodium/glucose channels in the intestinal mucosa. They act by inhibiting sodium-glucose transport protein 2 (SGLT2). SGLT2 inhibitors are used in the treatment of type II diabetes mellitus (T2DM).
Function - SGLT2 is a member of the sodium glucose cotransporter family which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney. SGLT2 is located in the early proximal tubule, and is responsible for reabsorption of 80-90% of the glucose filtered by the kidney glomerulus. Most of the remaining glucose absorption is by sodium/glucose cotransporter 1 (SGLT1) in more distal sections of the proximal tubule.
Sodium-glucose transporter 2 inhibitors - Sodium Glucose cotransporters (SGLTs) are proteins that occur primarily in the kidneys and play an important role in maintaining glucose balance in the blood. SGLT1 and SGLT2 are the two most known SGLTs of this family. SGLT2 is the major transport protein and promotes reabsorption from the glomerular filtration glucose back into circulation and is responsible for approximately 90% of the kidney's glucose reabsorption. SGLT2 is mainly expressed in the kidneys on the epithelial cells lining the first segment of the proximal convoluted tubule. By inhibiting SGLT2, gliflozins prevent the kidneys' reuptake of glucose from the glomerular filtrate and subsequently lower the glucose level in the blood and promote the excretion of glucose in the urine.
Sodium-glucose transporter 2 inhibitors Emerging Drugs Chapters
This segment of the Sodium-glucose transporter 2 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sodium-glucose transporter 2 inhibitors Emerging Drugs
- Farxiga (dapagliflozin): AstraZeneca
- Henagliflozin: Jiangsu HengRui Medicine
Further product details are provided in the report……..
Sodium-glucose transporter 2 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Sodium-glucose transporter 2 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Sodium-glucose transporter 2 inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Sodium-glucose transporter 2 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sodium-glucose transporter 2 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sodium-glucose transporter 2 inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Sodium-glucose transporter 2 inhibitors R&D. The therapies under development are focused on novel approaches for Sodium-glucose transporter 2 inhibitors.
- Sodium-glucose transporter 2 inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Sodium-glucose transporter 2 inhibitors drugs?
- How many Sodium-glucose transporter 2 inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Sodium-glucose transporter 2 inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sodium-glucose transporter 2 inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Sodium-glucose transporter 2 inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- AstraZeneca
- Jiangsu HengRui Medicine
- Chong Kun Dang Pharmaceutical
- Jeil Pharmaceutical
- Sirona Biochem
- Hanmi Pharmaceutical
- Chugai Pharmaceutical
- Daewoong
- Sihuan Pharmaceutical Holdings Group
- Theracos
- HEC Pharm
- Kissei Pharmaceutical
- Novartis Pharmaceuticals
- Youngene Therapeutics
- Lyndra
- Johnson & Johnson
- Farxiga (dapagliflozin)
- Henagliflozin
- Empagliflozin
- JP 2266
- SBM TFC 039
- HGP-1602
- Tofogliflozin
- Enavogliflozin
- Janagliflozin
- Bexagliflozin
- HEC44616
- Remogliflozin etabonate
- Licogliflozin
- YG 1699
- LYN?045
- JNJ-28431754
Introduction
Executive Summary
Sodium-glucose transporter 2 inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Sodium-glucose transporter 2 inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Sodium-glucose transporter 2 inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Sodium-glucose transporter 2 inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Farxiga (dapagliflozin): Amgen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tofogliflozin: Chugai Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
HGP-1602: Hanmi Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
JP 2266: Jeil Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Sodium-glucose transporter 2 inhibitors Key Companies
Sodium-glucose transporter 2 inhibitors Key Products
Sodium-glucose transporter 2 inhibitors- Unmet Needs
Sodium-glucose transporter 2 inhibitors- Market Drivers and Barriers
Sodium-glucose transporter 2 inhibitors- Future Perspectives and Conclusion
Sodium-glucose transporter 2 inhibitors Analyst Views
Sodium-glucose transporter 2 inhibitors Key Companies
Appendix
Executive Summary
Sodium-glucose transporter 2 inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Sodium-glucose transporter 2 inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Sodium-glucose transporter 2 inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Sodium-glucose transporter 2 inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Farxiga (dapagliflozin): Amgen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tofogliflozin: Chugai Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
HGP-1602: Hanmi Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
JP 2266: Jeil Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Sodium-glucose transporter 2 inhibitors Key Companies
Sodium-glucose transporter 2 inhibitors Key Products
Sodium-glucose transporter 2 inhibitors- Unmet Needs
Sodium-glucose transporter 2 inhibitors- Market Drivers and Barriers
Sodium-glucose transporter 2 inhibitors- Future Perspectives and Conclusion
Sodium-glucose transporter 2 inhibitors Analyst Views
Sodium-glucose transporter 2 inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Sodium-glucose transporter 2 inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Sodium-glucose transporter 2 inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Sodium-glucose transporter 2 inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Sodium-glucose transporter 2 inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
